Early clinical experience with risperidone long-acting injection: A prospective, 6-month follow-up of 100 patients

Journal of Clinical Psychiatry

Volumn 65, Issue 8, 2004, Pages 1076-1083

  Taylor, David M ^a   Young, Corina L ^a   Mace, Shubhra ^a   Patel, Maxine X ^b  

^a SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; RISPERIDONE;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; DRUG ADMINISTRATION; DRUG COMBINATION; FEMALE; HOSPITALIZATION; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; MIDDLE AGED; PATIENT; PATIENT ATTITUDE; PROSPECTIVE STUDY; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; PSYCHOSIS; SCHIZOPHRENIA; STATISTICS; TREATMENT OUTCOME; UNITED KINGDOM;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; COHORT STUDIES; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GREAT BRITAIN; HOSPITALIZATION; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT DROPOUTS; PHYSICIAN'S PRACTICE PATTERNS; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 4544241047     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v65n0808     Document Type: Article

References (17)

1. Grant S, Fitton A. Risperidone: a review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs 1994; 48:253-273 (Pubitemid 24260357)
2. Chue P, Eerdekens M, Augustyns I, et al. Efficacy and safety of long acting risperidone microspheres and risperidone oral tablets. Schizophr Res 2002;53(3 suppl 1):174-175
3. Kane JM, Eerdekens M, Lindenmayer JP, et al. Long acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003;160:1125-1132 (Pubitemid 41070972)
4. Turner M, Eerdekens M, Jacko M. Long acting risperidone: safety and efficacy in suitable patients switched from conventional depot anti-psychotics [poster]. Presented at the 156th annual meeting of the American Psychiatric Association; May 17-22, 2003; San Francisco, Calif
5. Eerdekens M, Fleischhaker WW, Xie Y, et al. Long term safety and efficacy of Risperdal Consta™, the long acting injection formulation of risperidone [abstract]. Int J Neuropsychopharmacol 2002;5(suppl 1):S126
6. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare. Rockville, Md: National Institute of Mental Health; 1976:157-169
7. Duggan L, Fenton M, Dardennes RM, et al. Olanzapine for schizophrenia (Cochrane Review). in: The Cochrane Library, Issue 3. Oxford, UK: Update Software; 2003
8. Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001;158:765-774 (Pubitemid 32429846)
9. Megna JL, Dewan M. A naturalistic study of risperidone maintenance treatment of outpatients with severe mental illness. Psychiatr Serv 1999; 50:1084-1086 (Pubitemid 29365376)
10. Weistedt B, Koskinen T, Thelander S, et al. Zuclopenthixol decanoate and haloperidol decanoate in chronic schizophrenia: a double-blind multicentre study. Acta Psychiatr Scand 1999;84:14-16
11. Eberhard G, Hellbom E. Haloperidol decanoate and flupenthixol decanoate in schizophrenia, a long term double blind cross over comparison. Acta Psychiatr Scand 1986;74:255-262 (Pubitemid 17175353)
12. Kane JM, Davis JM, Schooler N, et al. A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. Am J Psychiatry 2002;159:554-560 (Pubitemid 34274936)
13. Taylor DM, Wright T, Libretto SE, for the Risperidone Olanzapine Drug Outcomes Studies in Schizophrenia (RODOS) UK Investigator Group. Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis. J Clin Psychiatry 2003;64:589-597
14. Taylor DM, Duncan-McConnell D. Refractory schizophrenia and atypical antipsychotics. J Psychopharmacol 2000;14:409-418 (Pubitemid 32059788)
15. Expert Consensus Guideline Series: Treatment of Schizophrenia 1999. J Clin Psychiatry 1999;60(suppl 10:1-80
16. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60:553-564 (Pubitemid 36682312)
17. Leucht S, Wahlbeck K, Hamann J, et al. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003;361:1581-1589 (Pubitemid 36578993)